Impact of Covid-19 in Congenital Heart Disease

Summary

The ongoing Coronavirus (Covid-19) pandemic has recently generated the first epidemiological data on populations at risk. Currently, the risk factors, recognized for severe forms of Covid-19 infection, are elderly patients (\> 70 years), obese patients, patients with chronic renal or respiratory diseases, cardiovascular history (stroke or coronary artery disease), high blood pressure, diabetes, and cancer.

The population of congenital heart disease (CHD) might also be at risk, however, no data is available in this group of patients.

CHD is the leading cause of birth defects, and as a result of recent medical advances, currently the number of adults with CHD exceeds the number of children, with an increasing prevalence of complex CHD. Approximately 200,000 children and 250,000 adults are living with a CHD in France today.

The French Society of Cardiology, coordinator of this study, issued recommendations on March 14, 2020 for the French CHD population on the basis of expert opinions based essentially on the data published in the general population. Nevertheless, there is a need to provide scientific data on the impact of Covid-19 in the pediatric and adult CHD population.

This study aims to assess the morbidity, the mortality and the risk factors associated with Covid-19 in patients with CHD in France

Conditions

• Congenital Heart Disease
• Covid-19

Sponsors & Collaborators

• Pr. Jean-Benoît THAMBO, Bordeaux (président)

  collaborator UNKNOWN

• Dr. Céline GRUNENWALD GRONIER, Strasbourg

  collaborator UNKNOWN

• Dr. Sébastien HASCOET, Le Plessis-Robinson

  collaborator UNKNOWN

• Dr. Adeline BASQUIN, Rennes

  collaborator UNKNOWN

• Dr. Nicolas COMBES, Toulouse

  collaborator UNKNOWN

• Dr. Xavier IRIART, Bordeaux

  collaborator UNKNOWN

• Dr. Daniela LAUX, Paris

  collaborator UNKNOWN

• Dr. Magalie LADOUCEUR, Paris

  collaborator UNKNOWN

• Pr. BERTRAND LEOBON, Toulouse

  collaborator UNKNOWN

• Pr. Caroline OVAERT, Marseille

  collaborator UNKNOWN

• Dr. Karine WARIN-FRESSE, Nantes

  collaborator UNKNOWN

• Alexis BLANC, Montpellier

  collaborator UNKNOWN

• Pr. Roland HENAINE, Lyon

  collaborator UNKNOWN

• Hamouda ABASSI, Montpellier

  collaborator UNKNOWN

• University Hospital, Montpellier

  lead OTHER

Principal Investigators

• Pascal AMEDRO, MD-PhD · UH MONTPELLIER

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-03-01

Primary Completion

2020-12-01

Completion

2020-12-30

Countries

• France

Study Locations